A reader wrote:
“Dear CFS Remission, I have had ‘CFS’ for 17 years but I think I may have been misdiagnosed. My new doctor highly suspects some bug and wants me to do the full lyme test at iGeneX. I have never tested for thick blood and wonder if this could influence test results.”
The lyme test will likely give a weak positive. Not because you have Lyme but because you have had EBV or related virus in the past. Remember, we never get rid of a virus — instead, our immune system keep it suppress (usually).
With CFS, virii can become mildly reactivated — and this is just enough to give a false-positive for Lyme. Mine did. To my physician, it allowed her to justify the multiple rotating antibiotics (which we negotiated one by one) that worked the last time with me. Justifying the use of antibiotics is one of the biggest hurdles for MDs — despite success with them being reported. It is NOT pro-forma medical practice for CFS.
If you can arrange to have you microbiome tested in detail (i.e. ubiome.com or others) BEFORE you start the antibiotics — it should show significant shifts from normal. You want to make sure that the antibiotics prescribed are ALSO effective for reducing those overgrowths. The oldest detail studies on this shift that I am aware of are from Australia
- Faecal Microbial Growth Inhibition in Chronic Fatigue/Pain Patients 
- Two Case Studies of Successful Treatment of CFS/M.E. 
You can attempt to explain the model to your new MD. if s/he gets it then you could point to my blog and it’s pathological links to PubMed literature. Simplest explanation is this:
This is why fecal transplants resulting in remission works (at least temporarily). This is why MDs Jadin (South Africa), Bottelo (France), and Prof. Nicolson (US) have a good rate of remission with their antibiotic protocols for CFS [antibiotics do alter gut bacteria].
This should not influence the test. If you get tested for coagulation, it needs to be “throwing the book” at testing — that is all known coagulation abnormality, including testing for genetic defects. Dave Bergs result found that when testing for all defects in CFS patients that around 85-90% had detectable genetic defects and in researching, I found a professor class notes estimating that we know only about 80% of the cause or identification for hyper-coagulation. My own defect, Prothrombin G20210A, a european mutation only identified in the 1990’s illustrated that if I went to generic coagulation testings on my 2nd time with CFS — I would have been given a “No coagulation” report. Going to Hemex labs, specialists, came back with coagulation and inherited factor. Hence, “throwing the book” at coagulation testing is wise.